- Home
- HXHX vs MBRX Comparison
HXHX vs MBRX Comparison
Compare HXHX & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HXHX | MBRX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | China | United States |
| Employees | 85 | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HXHX | MBRX |
|---|---|---|
| Price | $0.45 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 96.0K | ★ 247.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.25 |
| 52 Week High | $2.15 | $7.98 |
Technical Indicators
Market Signals| Indicator | HXHX | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 33.86 |
| Support Level | $0.34 | $0.37 |
| Resistance Level | $0.55 | $5.15 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 25.85 | 42.86 |
Price Performance
Historical ComparisonAbout HXHX Haoxin Holdings Limited Class A Ordinary Shares
Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.